Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Mobility segment growing at 25% to 30% year-on-year; anticipated further growth with expansion into 4-5 more states, covering nearly 60% of India. New-age business is growing at 20-25% year-on-year; vintage (legacy) business expected to grow 12-18% yearly over next 5-7 years.
From Fredun Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Mobility segment growing at 25% to 30% year-on-year; anticipated further growth with expansion into 4-5 more states, covering nearly 60% of India.
- New-age business (including mobility, dermaceutics, cosmetics, pet care, nutraceuticals) targeting 20% to 25% annual growth; expected to constitute 51% of total business by 2029-30.
- Legacy (vintage) business expected to grow at 12% to 18% year-on-year for the next 5-7 years, supported by 1,300-1,400 registrations in the pipeline.
- Expansion into physiotherapy products and retail outlets ongoing, adding 30-40 outlets per week.
- Business scaling with a mix of in-house and asset-light manufacturing approaches to support growth.
2 more points from Fredun Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fredun Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Fredun Pharmaceuticals is currently expanding production capacities at existing plants and has added new partner manufacturing facilities across various locations (around 37 partner facilities).
- The company is focused on asset-light manufacturing, especially for new-age products, using third-party manufacturers to leverage cost efficiencies.
- No immediate requirement for fund-raising or capital infusion is anticipated in the next 12 to 18 months due to internal cash flows and recent fundraise.
2 more points from Fredun Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fredun Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Fredun Pharmaceuticals has about 1,300 to 1,400 registrations in the pipeline, which will keep contributing to growth over the next 5 to 7 years.
- These registrations represent pending orders or approvals that will enable business expansion.
- The company expects the legacy (vintage) business to grow around 12% to 18% year-on-year, supported by these registrations.
2 more points from Fredun Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Fredun Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹213 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fredun Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fredun Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fredun Pharmaceuticals Ltd Q3 FY26 results?
Mobility segment growing at 25% to 30% year-on-year; anticipated further growth with expansion into 4-5 more states, covering nearly 60% of India. New-age business is growing at 20-25% year-on-year; vintage (legacy) business expected to grow 12-18% yearly over next 5-7 years.
What is Fredun Pharmaceuticals Ltd share price analysis?
Fredun Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 57.6 with a market cap of ₹2,560 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fredun Pharmaceuticals Ltd planning capital expenditure?
Fredun Pharmaceuticals is currently expanding production capacities at existing plants and has added new partner manufacturing facilities across various locations (around 37 partner facilities).
Keep Fredun Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.